Oncomatryx Announces a €15 Million Capital Increase to Conduct Clinical Trials Against the Tumor Micro-environment
Following 12 years of pioneering research activities, Oncomatryx is embarking on a new phase in the development of its tumor microenvironment targeted ADCs. OMTX705, the Crown Jewel, has already proven
Source: finanznachrichten.de